title: Streamlining lead discovery by aligning in silico and high-throughput screening.
abstract: Lead discovery in the pharmaceutical environment is largely an industrial-scale process in which it is typical to screen 1-5 million compounds in a matter of weeks using High Throughput Screening (HTS). This process is a very costly endeavor. Typically a HTS campaign of 1 million compounds will cost anywhere from $500000 to $1000000. There is consequently a great deal of pressure to maximize the return on investment by finding fast and more effective ways to screen. A panacea that has emerged over the past few years to help address this issue is in silico screening. In silico screening is now incorporated in all areas of lead discovery; from target identification and library design, to hit analysis and compound profiling. However, as lead discovery has evolved over the past few years, so has the role of in silico screening.
authors.affiliation: Lead Discovery Center, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, MA 02139, USA. john-w.davies@novartis.com
authors.forename: John W
authors.initials: JW
authors.lastname: Davies
authors.forename: Meir
authors.initials: M
authors.lastname: Glick
authors.forename: Jeremy L
authors.initials: JL
authors.lastname: Jenkins
mesh_terms: D001499:Bayes Theorem; D019295:Computational Biology; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D023281:Genomics